Loading
Latest filing published 13 Oct 2011 for MARIZYME, INC., €12k.
No signal scores available.
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
All filings by John Paul Durst on record concern Marizyme, Inc. We count 4 filings; the first trade dates from 14 September 2011 and the latest from 11 October 2011.
In open-market terms, that means 2 purchases worth €18k on one side and 2 sales worth €21k on the other. The net balance comes to €2,925 on the selling side. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay.
The newest entry dates from 13 October 2011: an open-market purchase of €12k, in Marizyme, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. US insiders must file a Form 4 within two business days of a trade. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
4 of 4 declarations